Mark Brosius Sells 492 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) Stock

Intuitive Surgical, Inc. (NASDAQ:ISRG) SVP Mark Brosius sold 492 shares of Intuitive Surgical stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $554.17, for a total value of $272,651.64. Following the completion of the transaction, the senior vice president now owns 3,072 shares of the company’s stock, valued at approximately $1,702,410.24. This trade represents a 13.80 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Mark Brosius also recently made the following trade(s):

• On Friday, March 7th, Mark Brosius sold 489 shares of Intuitive Surgical stock. The shares were sold at an average price of $533.18, for a total value of $260,725.02.
• On Monday, March 3rd, Mark Brosius sold 492 shares of Intuitive Surgical stock. The shares were sold at an average price of $573.78, for a total value of $282,299.76.

Intuitive Surgical Stock Down 3.8 %

Shares of NASDAQ ISRG opened at $518.26 on Friday. The stock has a market cap of $184.59 billion, a PE ratio of 80.85, a price-to-earnings-growth ratio of 5.85 and a beta of 1.43. Intuitive Surgical, Inc. has a 52-week low of $364.17 and a 52-week high of $616.00. The business has a 50-day moving average price of $571.36 and a 200 day moving average price of $531.20.

Institutional Trading of Intuitive Surgical

A number of hedge funds have recently added to or reduced their stakes in the stock. IronOak Wealth LLC. acquired a new stake in Intuitive Surgical during the 4th quarter worth approximately $1,595,000. TFR Capital LLC. acquired a new stake in Intuitive Surgical during the 4th quarter worth approximately $3,252,000. Siemens Fonds Invest GmbH lifted its position in Intuitive Surgical by 795.2% during the 4th quarter. Siemens Fonds Invest GmbH now owns 143,818 shares of the medical equipment provider’s stock worth $75,067,000 after acquiring an additional 127,753 shares during the period. BridgePort Financial Solutions LLC acquired a new stake in Intuitive Surgical during the 4th quarter worth approximately $330,000. Finally, Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in Intuitive Surgical during the 4th quarter worth approximately $167,943,000. 83.64% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts recently issued reports on ISRG shares. Bernstein Bank lifted their target price on Intuitive Surgical from $655.00 to $700.00 and gave the company an “overweight” rating in a report on Monday, January 27th. Raymond James lifted their price target on Intuitive Surgical from $560.00 to $688.00 and gave the stock an “outperform” rating in a report on Friday, January 24th. Morgan Stanley raised Intuitive Surgical from an “equal weight” rating to an “overweight” rating and lifted their price target for the stock from $522.00 to $650.00 in a report on Monday, December 2nd. Piper Sandler reaffirmed an “overweight” rating and set a $670.00 price target (up from $538.00) on shares of Intuitive Surgical in a report on Friday, January 24th. Finally, Jefferies Financial Group lifted their price target on Intuitive Surgical from $475.00 to $575.00 in a report on Monday, January 27th. One analyst has rated the stock with a sell rating, four have issued a hold rating and sixteen have given a buy rating to the company’s stock. According to MarketBeat.com, Intuitive Surgical currently has an average rating of “Moderate Buy” and a consensus target price of $613.10.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.